Is CTRE a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for CareTrust REIT (CTRE) rests on Acquisitions at a wide spread over cost of capital: CareTrust closed ~$900 million of investments in the second quarter at a ~8.9% blended stabilized yield, its largest non-M&A quarter, plus ~$308 million after quarter end at ~7.8%, taking deployment through early August to ~$1.5 billion at ~8.7%. The bear case rests on tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Analysts covering it publish targets from $41.00 to $49.00 against a $37.39 share price on November 16, 2026, so even the professionals disagree by 18% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

CTRE key stats

At $37.39 on November 16, 2026, CareTrust REIT (CTRE) has a market cap of $9.6B, a P/E of 23.5 on trailing earnings (19.9 on forward earnings) and a dividend yield of 4.17%.

Market cap
$9.6B
P/E (trailing)
23.5
P/E (forward)
19.9
EPS (trailing 12 months)
$1.59
Price to book
1.8
Dividend yield
4.17%
Beta
0.79

Market cap, P/E and yield are measured at the $37.39 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with CareTrust REIT (CTRE)?

The last two weeks for CareTrust REIT, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • CTRE closed at $37.39 on November 16, 2026, down 3.8% over the past five trading days (from $38.86).
  • On November 16, 2026, CareTrust REIT filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 13, 2026, CareTrust REIT filed an 8-K with the SEC reporting a material agreement and other events (Item 1.01, Item 8.01). Read the 8-K on sec.gov
  • On November 5, 2026, CareTrust REIT filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
  • On November 5, 2026, CareTrust REIT filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

CareTrust REIT owns healthcare real estate and does not operate any of it. The portfolio is mostly skilled nursing facilities, with a growing share of senior housing, assisted living and multi-service campuses, spread across roughly 30 US states and, since the 2025 acquisition of UK-listed Care REIT plc, the United Kingdom. Properties are leased to regional and national operators under triple-net structures, meaning the tenant pays taxes, insurance and maintenance and CareTrust collects contractual rent with annual escalators. The company was spun off from The Ensign Group in 2014, which is why Ensign remains its largest tenant, and it has since diversified into a roster where the top ten operators account for roughly 69% of rent. Alongside owned real estate it runs a mortgage and mezzanine loan book, which supplies a pipeline into future acquisitions. The investment picture in October 2026 is a growth REIT rather than a yield REIT. Second-quarter revenue of ~$161 million was up sharply from ~$113 million a year earlier, normalized FFO per share of ~$0.51 rose ~19%, and trailing twelve-month revenue reached ~$571 million. On October 2, 2026 CareTrust agreed to acquire 45 new UK care homes from LNT Care Developments for about GBP 1.1 billion (~$1.45 billion), closing the first 24 homes (~GBP 576 million) immediately and taking the remaining 21 as construction and approvals finish, as the start of a UK senior housing operating portfolio. With that deal it raised full-year normalized FFO guidance for a second time, to $2.06 to $2.09 per share from $2.03 to $2.06. Net debt sat around 1.0x annualized normalized run-rate EBITDA at the end of June, an unusually light balance sheet for a REIT. At a $36.62 share price and ~$8.65 billion market capitalization the stock trades near 18x guided 2026 normalized FFO with a ~4.3% dividend yield. The shares are up about 1% year to date and about 8% over one year, but down about 16% over three months. The trade-off is concentration and policy: Ensign is ~21% of annualized rent, PACS Group is ~10% and has been dealing with a federal investigation and shareholder litigation of its own, and nearly all US operator revenue ultimately traces back to Medicare and Medicaid.

The bull case: what would have to be true for $49.00

The most optimistic published target on CTRE is $49.00, +31.1% from the $37.39 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Acquisitions at a wide spread over cost of capital

CareTrust closed ~$900 million of investments in the second quarter at a ~8.9% blended stabilized yield, its largest non-M&A quarter, plus ~$308 million after quarter end at ~7.8%, taking deployment through early August to ~$1.5 billion at ~8.7%. The October LNT agreement adds up to ~$1.45 billion more in the UK, and management cited a further ~$525 million of near-term actionable opportunities excluding the 21 LNT homes still under contract. External growth is the engine: every dollar placed at attractive yields against a lower blended funding cost lands in FFO per share, which is why guidance implies mid-to-high-teens per-share growth rather than the low single digits typical of mature net-lease REITs.

2. A balance sheet with almost no leverage

Net debt to annualized normalized run-rate EBITDA was ~1.0x at the end of the second quarter, down from ~2.0x a year earlier, against ~$1.2 billion of total debt that is ~74% fixed rate. Liquidity at that point included ~$90 million of cash, ~$605 million available on the revolver and ~$671 million of unsettled equity forwards. In a sector where 5x to 6x leverage is normal, that capacity is the option value: it lets CareTrust keep buying when higher-levered peers are forced to pause. The size of the LNT deal means leverage reported for the third quarter is worth watching against that ~1.0x starting point.

3. A covered dividend with room to grow

The quarterly dividend is $0.39 per share, or ~$1.56 annualized, which works out to roughly a 4.3% yield at $36.62 and was about 76% of normalized FAD at the earlier guidance midpoint. Rent collection has run at 100% of contractual amounts, and rent escalators are assumed at ~2.5% for 2026. The payout ratio matters more than the headline yield here, because a REIT growing FFO per share in the mid teens with a payout in the seventies can raise the dividend from cash flow rather than from new share issuance.

4. Demographics against a supply that has not grown

The 80-plus population is entering its fastest growth stretch in decades while new skilled nursing construction has been effectively flat for years, so occupancy and rate pressure have moved in operators' favor. CMS also rescinded the federal minimum staffing rule effective February 2026, removing a mandate operators had said would be unfundable. Both effects reach CareTrust indirectly, through the rent coverage of its tenants, but stronger operator margins are what make lease escalators and future rent resets collectible. The UK operating platform taps the same aging trend under a different payer system.

The bear case: what would have to be true for $41.00

The most pessimistic published target is $41.00, +9.7% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks CareTrust REIT is worth if the risks below bite instead of the drivers above.

Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Reimbursement policy sits underneath everything, since US operators are paid mostly by Medicare and Medicaid, and the 2025 federal law steps the state provider tax cap down from 6% to 3.5% by fiscal 2032 in Medicaid expansion states while individual states debate their own rate cuts. The growth model itself is a dependency: mid-teens FFO per share growth requires continuously issuing equity and finding deals at attractive yields, and if either the equity window closes or cap rates compress, the growth rate resets to escalators alone. The UK expansion raises the stakes on that model: an operating portfolio carries occupancy and cost risk that a triple-net lease passes to the tenant, the second LNT tranche depends on construction and regulatory approvals, and rent is earned in pounds while results are reported in dollars. Interest rates cut both ways, raising the cost of the debt CareTrust has not yet drawn and setting the yield investors demand on the stock. Sentiment has cooled too: the stock fell about 16% over three months to October 16, 2026, and JPMorgan initiated coverage at Neutral with a $41 target that day.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CTRE already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on CTRE

14 analysts cover CTRE, with an average target of $43.64 (+16.7% against $37.39) and a split of 12 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CTRE forecast and price target page.

How is CTRE valued?

Market cap, P/E and dividend yield at today's price are in the CTRE key stats above. The business figures below come from CareTrust REIT's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$571 million, with Q2 2026 at ~$161 million versus ~$113 million a year earlier (~+43%)
  • Normalized FFO per share (Q2 2026): ~$0.51, up ~19% year over year
  • FY2026 normalized FFO per share guidance: ~$2.06 to $2.09, raised in October from $2.03 to $2.06
  • Net income (TTM): ~$356 million, ~$1.60 per share
  • Dividend: ~$0.39 per quarter, ~$1.56 annualized, roughly a 4.3% yield
  • Price to 2026 normalized FFO: ~18x at a $36.62 share price and ~$8.65 billion market cap
  • Net debt to annualized normalized run-rate EBITDA: ~1.0x at end of Q2 2026, down from ~2.0x a year earlier

As of October 2026: Trailing net income of ~$356 million (~$1.60 per share, ~23x on a P/E basis) understates the cash the business generates, because REIT accounting charges large non-cash depreciation against buildings that are not actually losing value, which is why guidance and the dividend are both framed against normalized FFO and FAD. At ~18x the raised FFO guidance, the multiple has compressed from ~19x in August as the shares slid, leaving it above most skilled nursing landlords and below the diversified large-cap healthcare REITs. Analysts' mean target is about $43.79 across 14 analysts, and third-quarter results are expected around November 9, 2026, with consensus EPS near $0.43 on ~$158 million of revenue.

How do you decide if CTRE is a buy?

Whether CTRE is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold CTRE indirectly through an index or sector ETF before adding more.

What would change your mind on CTRE

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Acquisitions at a wide spread over cost of capital stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the CTRE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CTRE against your real portfolio and see your actual exposure before deciding.

Your questions about CareTrust REIT

Ask Walnut's AI anything about CTRE and see how it fits what you own.

FAQ

Is CTRE a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Acquisitions at a wide spread over cost of capital, with revenue (ttm) at ~$571 million, with Q2 2026 at ~$161 million versus ~$113 million a year earlier (~+43%). The bear case rests on tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Analysts covering it are spread from $41.00 to $49.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell CTRE?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $41.00, +9.7% from the $37.39 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for CTRE?

+

Acquisitions at a wide spread over cost of capital. CareTrust closed ~$900 million of investments in the second quarter at a ~8.9% blended stabilized yield, its largest non-M&A quarter, plus ~$308 million after quarter end at ~7.8%, taking deployment through early August to ~$1.5 billion at ~8.7%. The most optimistic analyst target on CTRE is $49.00, +31.1% from the $37.39 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for CTRE?

+

Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Reimbursement policy sits underneath everything, since US operators are paid mostly by Medicare and Medicaid, and the 2025 federal law steps the state provider tax cap down from 6% to 3.5% by fiscal 2032 in Medicaid expansion states while individual states debate their own rate cuts. The growth model itself is a dependency: mid-teens FFO per share growth requires continuously issuing equity and finding deals at attractive yields, and if either the equity window closes or cap rates compress, the growth rate resets to escalators alone. The UK expansion raises the stakes on that model: an operating portfolio carries occupancy and cost risk that a triple-net lease passes to the tenant, the second LNT tranche depends on construction and regulatory approvals, and rent is earned in pounds while results are reported in dollars. Interest rates cut both ways, raising the cost of the debt CareTrust has not yet drawn and setting the yield investors demand on the stock. Sentiment has cooled too: the stock fell about 16% over three months to October 16, 2026, and JPMorgan initiated coverage at Neutral with a $41 target that day. The most pessimistic published target is $41.00, +9.7% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does CareTrust REIT do?

+

Net-lease owner of skilled nursing and seniors housing property, leased to operators such as Ensign and PACS, carrying almost no leverage.

What would have to change for CTRE to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Acquisitions at a wide spread over cost of capital) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does CareTrust REIT actually own?

+

CareTrust owns the real estate, not the care business. Its portfolio is mostly skilled nursing facilities plus senior housing, assisted living and multi-service campuses across roughly 30 US states and, following the 2025 purchase of Care REIT plc, the United Kingdom. Third-party operators run the facilities under long-term triple-net leases and pay taxes, insurance and maintenance themselves. CareTrust also holds a book of mortgage and mezzanine loans to operators, and in October 2026 it began building a UK senior housing operating portfolio with 45 new care homes from LNT Care Developments.

Why is FFO used instead of earnings per share for CTRE?

+

REIT accounting requires large depreciation charges on buildings that generally hold or grow in value, so GAAP net income systematically understates cash generation. Funds from operations adds depreciation back; funds available for distribution goes further and subtracts recurring capital costs and non-cash rent. CareTrust reported ~$0.38 of diluted EPS in the second quarter of 2026 against ~$0.51 of normalized FFO per share, and it guides and pays the dividend off the latter.

How concentrated is CareTrust in a single tenant?

+

Concentrated, though less than it once was. The Ensign Group, from which CareTrust was spun off in 2014, is around 21% of annualized rent, PACS Group is roughly 10% and Priority Management Group about 7%, based on mid-2026 disclosures. The top ten operators together account for roughly 69% of rent, leaving about 31% spread across smaller regional operators. Ensign's share has fallen steadily as the portfolio has grown, but it remains the single largest exposure to watch.

Walnut is informational, not investment advice, and gives no verdict on CTRE. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks